2017-18 HSC Section 4 Green Book

B E L E ZNAY E T A L

United States 42

Taiwan 41

Vision: 20/200 Korea 44

97 NR Nasal dorsum Within 1 day: LE NR Intraocular pressure lowering LE vision: 20/20 Korea 23 98 NR Eyelid Within 2 days: RE vision: 20/20 NR Anticoagulant RE vision: 20/20 Korea 23 CaHA, calcium hydroxylapatite; CO 2

NR NR NR 43

for Follow-up) Country

Outcome

Case Type of Filler Injection Site Symptoms Signs Management 93 Polyacrylamide hydrogel (Aquamid), botulinum toxin Type A NR, likely periocular Immediate: nausea, vomiting. Left upper eye visual field defect for 3 days when reported. LE vision: 20/70 Ophthalmoplegia, ptosis, transient third nerve palsy. Edema, erythema, pustules, and cellulitis from glabella to nasojugal folds Oral steroids, IV antibiotics, aspirin 94 Cymetra (micronized dermal matrix) Forehead Ptosis, exotropia NR LE vision: light perception, hypertropia, exotropia LE vision: 20/30 with superior half visual field defect

(Variable Time

, carbon dioxide; LE, left eye; MCA, middle cerebral artery; NR, not reported; O 2 , oxygen; PLLA, poly- L -lactic acid; PMMA, polymethyl methacrylate; RE, right

Immediate: LE vision loss Erythema to injection sites Acetazolamide (1 week), IV methylprednisolone (3 days) vision: 20/32

Subsequent necrosis to the glabella

95 NR Glabella Immediate: vision loss 96 NR Glabella, perinasal,

10 minutes: nausea, diaphoresis. Subsequent: LE

pain. 30 minutes later: LE vision: hand motion

periorbital

(depressed scar)

TABLE 1. (Continued)

eye; SAH, subarachnoid hemorrhage.

4 1 : 1 0 : OCTOB E R 2 0 1 5

71